HC Wainwright Reaffirms “Buy” Rating for Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Friday, MarketBeat.com reports. They currently have a $1.00 price target on the stock, down from their previous price target of $3.00. HC Wainwright’s target price suggests a potential upside of 176.24% from the company’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Trading Down 1.6%

VRAX opened at $0.36 on Friday. The firm has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.62. Virax Biolabs Group has a twelve month low of $0.31 and a twelve month high of $2.61.

Virax Biolabs Group (NASDAQ:VRAX) last announced its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The company had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.